Kite Pharma's Lead Program With The National Cancer Institute (NCI) Demonstrates Positive Results In Patients With Aggressive Non-Hodgkin's Lymphoma
"These clinical results are extremely encouraging and further validate both the CD19 target and the overall eACT approach," said Keith Nolop, MD, Chief Medical Officer of Kite Pharma. "These patients have aggressive disease that is resistant to chemotherapy, and they have no viable treatment options other than a clinical trial. Both the high overall response rate and the durability of the responses are noteworthy."
Arie Belldegrun, MD, Founder and Executive Chairman of the Board of Kite Pharma, added, "Our collaboration with the NCI has been highly productive and rewarding. Given the dramatic responses achieved so far, Kite is fully committed to rapidly advance the clinical development of the CAR technology for multiple indications. We look forward to bringing this promising therapy to patients with advanced cancer."
About the eACT Platform
Clinical evidence has demonstrated that a patients' peripheral blood T cells, which have been engineered with T cell receptor (TCRs) and chimeric antigen receptors (CARs) that recognize tumor specific molecules, can traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors. Clinical studies performed at the National Cancer Institute (NCI) using these types of engineered peripheral blood T cells have been associated with significant and durable objective clinical responses in cancer patients with advanced metastatic disease, including those with refractory melanoma, sarcoma, lymphoma and leukemia. These encouraging results highlight eACT as an emerging therapeutic modality that could provide new personalized targeted therapy options for cancer patients spanning the spectrum of disease from its early stages to the salvage setting.About Kite Pharma Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products, with a major focus on eACT therapy designed at restoring the patient's immune system to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA. For more information, visit the company's website at http://www.kitepharma.com. Kite Contact:Dr. Arie BelldegrunExecutive Chairman310-824-9999 firstname.lastname@example.org For Media: Justin JacksonBurns McClellan(212) 213-0006 email@example.com SOURCE Kite Pharma, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts